The Role of Immunotherapy in Esophageal and Gastric Cancer

Siegel, 2015, Cancer statistics, CA Cancer J Clin, 65, 5, 10.3322/caac.21254 Siewert, 2007, Are squamous and adenocarcinomas of the esophagus the same disease?, Semin Radiat Oncol, 17, 38, 10.1016/j.semradonc.2006.09.007 Rustgi, 2014, Esophageal Carcinoma, New England Journal of Medicine, 371, 2499, 10.1056/NEJMra1314530 Castro, 2014, Patterns and trends in esophageal cancer mortality and incidence in Europe (1980-2011) and predictions to 2015, Ann Oncol, 25, 283, 10.1093/annonc/mdt486 Smyth, 2016, Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 27, v38, 10.1093/annonc/mdw350 Siewert, 1996, Carcinoma of the gastroesophageal junction - classification, pathology and extent of resection, Diseases of the Esophagus, 9, 173 Siewert, 1998, Classification of adenocarcinoma of the oesophagogastric junction, Br J Surg, 85, 1457, 10.1046/j.1365-2168.1998.00940.x Amin, 2017, The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging, CA Cancer J Clin, 67, 93, 10.3322/caac.21388 Obermannová, 2022, Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up, Ann Oncol, 33, 992, 10.1016/j.annonc.2022.07.003 Naimi, 2022, Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons, Cell Commun Signal, 20, 44, 10.1186/s12964-022-00854-y Doroshow, 2021, PD-L1 as a biomarker of response to immune-checkpoint inhibitors, Nat Rev Clin Oncol, 18, 345, 10.1038/s41571-021-00473-5 Jiang, 2019, PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations, Hum Vaccin Immunother, 15, 1111, 10.1080/21645515.2019.1571892 Qin, 2019, Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4, Mol Cancer, 18, 155, 10.1186/s12943-019-1091-2 Xia, 2019, PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions, Oncologist, 24, S31, 10.1634/theoncologist.2019-IO-S1-s05 Gandhi, 2018, Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer, N Engl J Med, 378, 2078, 10.1056/NEJMoa1801005 Paz-Ares, 2019, Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial, Lancet, 394, 1929, 10.1016/S0140-6736(19)32222-6 Horn, 2018, First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer, N Engl J Med, 379, 2220, 10.1056/NEJMoa1809064 Vrána, 2017, Current Status of Checkpoint Inhibitors in the Treatment of Esophageal and Gastric Tumors - Overview of Studies, Klin Onkol, 31, 35 Smith, 2022, Immunotherapy use in oesophagogastric cancers-a review of the literature, Br J Cancer, 127, 21, 10.1038/s41416-022-01751-4 Sun, 2020, Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives, Biomark Res, 8, 35, 10.1186/s40364-020-00212-5 Gibney, 2016, Predictive biomarkers for checkpoint inhibitor-based immunotherapy, Lancet Oncol, 17, e542, 10.1016/S1470-2045(16)30406-5 Shitara, 2018, Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial, Lancet, 392, 123, 10.1016/S0140-6736(18)31257-1 Liu, 2021, Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma, Sci Rep, 11, 15907, 10.1038/s41598-021-95372-1 Shen, 2022, Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study, J Clin Oncol, 40, 3065, 10.1200/JCO.21.01926 Yamashita, 2020, Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer, Gastric Cancer, 23, 95, 10.1007/s10120-019-00999-9 Kim, 2021, Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimens, Pathology, 53, 586, 10.1016/j.pathol.2020.10.015 Shi, 2019, A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma, Mod Pathol, 32, 1646, 10.1038/s41379-019-0307-8 Eto, 2016, Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection, Gastric Cancer, 19, 466, 10.1007/s10120-015-0519-7 Mahoney, 2015, PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells, Cancer Immunol Res, 3, 1308, 10.1158/2326-6066.CIR-15-0116 Sun, 2016, Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies, J Transl Med, 14, 173, 10.1186/s12967-016-0925-6 Sunshine, 2017, PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison, Clin Cancer Res, 23, 4938, 10.1158/1078-0432.CCR-16-1821 Rimm, 2017, A Prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer, JAMA Oncol, 3, 1051, 10.1001/jamaoncol.2017.0013 McGranahan, 2016, Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, 351, 1463, 10.1126/science.aaf1490 Rizvi, 2018, Molecular determinants of response to anti-programmed cell death (pd)-1 and anti-programmed death-ligand 1 (pd-l1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing, J Clin Oncol, 36, 633, 10.1200/JCO.2017.75.3384 Hellmann, 2018, Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden, N Engl J Med, 378, 2093, 10.1056/NEJMoa1801946 Samstein, 2019, Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat Genet, 51, 202, 10.1038/s41588-018-0312-8 Shrestha, 2018, Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma, Front Oncol, 8, 269, 10.3389/fonc.2018.00269 Hanna, 2018, Frameshift events predict anti-PD-1/L1 response in head and neck cancer, JCI Insight, 3, e98811, 10.1172/jci.insight.98811 Goodman, 2017, Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers, Mol Cancer Ther, 16, 2598, 10.1158/1535-7163.MCT-17-0386 Cristescu, 2018, Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy, Science, 362, 10.1126/science.aar3593 Yarchoan, 2017, Tumor mutational burden and response rate to PD-1 inhibition, N Engl J Med, 377, 2500, 10.1056/NEJMc1713444 Vrána, 2018, From tumor immunology to immunotherapy in gastric and esophageal cancer, Int J Mol Sci, 20, 13, 10.3390/ijms20010013 Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733 Yan, 2018, Precision medicine becomes reality-tumor type-agnostic therapy, Cancer Commun (Lond), 38, 6, 10.1186/s40880-018-0274-3 Dudley, 2016, Microsatellite instability as a biomarker for PD-1 blockade, Clin Cancer Res, 22, 813, 10.1158/1078-0432.CCR-15-1678 Marabelle, 2020, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study, J Clin Oncol, 38, 1, 10.1200/JCO.19.02105 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 Blum Murphy, 2017, Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival—the University of Texas MD Anderson Cancer Center experience, Cancer, 123, 4106, 10.1002/cncr.30953 Kelly, 2021, Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer, N Engl J Med, 384, 1191, 10.1056/NEJMoa2032125 Zhang, 2021, Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs, Signal Transduct Target Ther, 6, 314, 10.1038/s41392-021-00722-0 Lordick, 2016, Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 27, v50, 10.1093/annonc/mdw329 Lordick, 2013, Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial, Lancet Oncol, 14, 490, 10.1016/S1470-2045(13)70102-5 Shah, 2017, Effect of Fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial, JAMA Oncol, 3, 620, 10.1001/jamaoncol.2016.5580 Doki, 2022, Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma, N Engl J Med, 386, 449, 10.1056/NEJMoa2111380 Sun, 2021, Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study, Lancet, 398, 759, 10.1016/S0140-6736(21)01234-4 Shitara, 2020, Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial, JAMA Oncol, 6, 1571, 10.1001/jamaoncol.2020.3370 van Cutsem, 2015, HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer, Gastric Cancer, 18, 476, 10.1007/s10120-014-0402-y Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X Janjigian, 2021, The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer, Nature, 600, 727, 10.1038/s41586-021-04161-3 Janjigian, 2021, First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial, Lancet, 398, 27, 10.1016/S0140-6736(21)00797-2 Ajani, 2022, Gastric cancer, Version 2.2022, NCCN clinical practice guidelines in Oncology, J Natl Compr Canc Netw, 20, 167, 10.6004/jnccn.2022.0008 Lordick, 2022, Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up, Ann Oncol, 33, 1005, 10.1016/j.annonc.2022.07.004 Kato, 2019, Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol, 20, 1506, 10.1016/S1470-2045(19)30626-6 Marabelle, 2020, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, Lancet Oncol, 21, 1353, 10.1016/S1470-2045(20)30445-9 National Comprehensive Cancer Network. Esophageal and Esophagogastric Junction Cancers Version 1. 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed March 2nd, 2023. Park, 2020, PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs, Cancer Res Treat, 52, 661, 10.4143/crt.2019.718 Zhou, 2020, Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy, Clin Cancer Res, 26, 6453, 10.1158/1078-0432.CCR-20-2085 Zhao, 2022, Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma, J Clin Oncol, 40, 392, 10.1200/JCO.21.01862 Yoon, 2022, Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials, JAMA Oncol, 8, 1456, 10.1001/jamaoncol.2022.3707 Leone, 2022, Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score, ESMO Open, 7, 10.1016/j.esmoop.2021.100380 Chalmers, 2017, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, 9, 34, 10.1186/s13073-017-0424-2 Jardim, 2021, The challenges of tumor mutational burden as an immunotherapy biomarker, Cancer Cell, 39, 154, 10.1016/j.ccell.2020.10.001 Janjigian, 2022, MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer, Future Oncol, 18, 2465, 10.2217/fon-2022-0093 Smyth, 2019, VESTIGE: adjuvant immunotherapy in patients with resected esophageal, gastroesophageal junction and gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study, Front Oncol, 9, 1320, 10.3389/fonc.2019.01320 Raimondi, 2021, TremelImumab and durvalumab combination for the non-operative management (NOM) of microsatellite instability (MSI)-high resectable gastric or gastroesophageal junction cancer: the multicentre, single-arm, multi-cohort, phase II infinity study, Cancers (Basel), 13, 2839, 10.3390/cancers13112839 Sun, 2022, LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma, J Clin Oncol, 40